Montreal Immune-Related Adverse Events (MIRAE) Study (MIRAE Trial)
Palo Alto (17 mi)Overseen byMarie Hudson, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Recruiting
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
No Placebo Group
Trial Summary
What is the purpose of this trial?Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be life-threatening in extreme cases. The causes of irAEs are largely unknown and there are no reliable predictive biomarkers. The Montreal Immune-Related Adverse Events (MIRAE) study collects clinical information and biospecimens (blood, tissue, stool) from cancer patients treated with ICI to facilitate research on the identification of predictive biomarkers of irAEs, their causes, and the design of effective management strategies.
Eligibility Criteria
Treatment Details
Find a clinic near you
Research locations nearbySelect from list below to view details:
Jewish General HospitalMontreal, Canada
Loading ...
Who is running the clinical trial?
Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor